Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RT 001

Next Previous
Drug Profile

RT 001

Alternative Names: Di-deuterated ethyl linoleate; Di-deuterated linoleic acid ethyl ester; RT-001 - Retrotope; RT001

Latest Information Update: 15 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Retrotope
  • Developer BioJiva; Retrotope
  • Class Antidementias; Antiparkinsonians; Antivirals; Neuroprotectants; Unsaturated fatty acids
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroaxonal dystrophies; Neurodegenerative disorders; Progressive supranuclear palsy; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Neuroaxonal dystrophies
  • Phase II Amyotrophic lateral sclerosis; Progressive supranuclear palsy
  • Discontinued Alzheimer's disease; COVID 2019 infections; Friedreich's ataxia; Huntington's disease; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 15 Sep 2022 Retrotope completes a phase II trial in Amyotrophic lateral sclerosis in Estonia, Latvia, the Netherlands and Sweden (PO) (NCT04762589)
  • 15 Sep 2022 Efficacy data from a phase II trial in amyotrophic lateral sclerosis released by BioJiva
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top